Mafalda Oliveira discusses ESR1m ctDNA in MBC patients treated by camizestrant

The European Society for Medical Oncology (ESMO) posted on LinkedIn:

“For ESMO members: Breaking Science in Breast Cancer.
Mafalda Oliveira discusses ESR1m ctDNA in MBC patients treated by camizestrant.
Watch her presentation and other impactful videos on OncologyPRO now.”

Source: The European Society for Medical Oncology (ESMO)/LinkedIn
.
The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.